Gastroenterology
Volume 130, Issue 3 , Pages 940-987 , March 2006

American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease

  • Gary R. Lichtenstein

      Affiliations

    • Hospital of the University of Pennsylvania University of Pennsylvania School of Medicine Philadelphia, Pennsylvania
    • Corresponding Author InformationAddress requests for reprints to: Chair, Clinical Practice and Economics Committee, AGA National Office, c/o Membership Department, 4930 Del Ray Avenue, Bethesda, Maryland 20814. fax: (301) 654-5920
  • Maria T. Abreu

      Affiliations

    • Mount Sinai School of Medicine Mount Sinai Medical Center New York, New York
  • Russell Cohen

      Affiliations

    • University of Chicago Hospitals University of Chicago School of Medicine Chicago, Illinois
  • William Tremaine

      Affiliations

    • Mayo Clinic College of Medicine Mayo Clinic Rochester, Minnesota

References 

  1. Crohn B , Ginzburg L , Oppenheimer GR . Regional ileitis (A pathologic and clinical entity) . JAMA . 1932;99:1323–1329
  2. Wilks S, Moxon W. Lectures on pathological anatomy. 2nd ed. Philadelphia, PA: Lindsay and Blakiston, 1875.
  3. Amsterdam A , Tajima K , Sasson R . Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action . Biochem Pharmacol . 2002;64:843–850
  4. Clark AR , Lasa M . Crosstalk between glucocorticoids and mitogen-activated protein kinase signaling pathways . Curr Opin Pharmacol . 2003;3:404–411
  5. Kagoshima M , Ito K , Cosio B , Adcock IM . Glucocorticoid suppression of nuclear factor-kappa B: a role for histone modifications . Biochem Soc Trans . 2003;31:60–65
  6. De Bosscher K , Vanden Berghe W , Haegeman G . The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression . Endocr Rev . 2003;24:488–522
  7. Hayashi R , Wada H , Ito K , Adcock IM . Effects of glucocorticoids on gene transcription . Eur J Pharmacol . 2004;500:51–62
  8. Goulding NJ . The molecular complexity of glucocorticoid actions in inflammation—a four-ring circus . Curr Opin Pharmacol . 2004;4:629–636
  9. Buttgereit F , Saag KG , Cutolo M , da Silva JA , Bijlsma JW . The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis . Scand J Rheumatol . 2005;34:14–21
  10. Scheinman RI , Cogswell PC , Lofquist AK , Baldwin AS . Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids . Science . 1995;270:283–286
  11. Tao Y , Williams-Skipp C , Scheinman RI . Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis . J Biol Chem . 2001;276:2329–2332
  12. Lofberg R, Danielsson A, Suhr O, Suhr O, Nilsson A, Schioler R, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis . Gastroenterology . 1996;110:1713–1718
  13. Bar-Meir S, Chowers Y, Lavy A, Lavy A, Abramovitch D, Sternberg A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease (The Israeli Budesonide Study Group) . Gastroenterology . 1998;115:835–840
  14. Dahlberg E, Thalen A, Brattsand R, Brattsand R, Gustafsson JA, Johansson U, et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids . Mol Pharmacol . 1984;25:70–78
  15. Spencer CM , McTavish D . Budesonide (A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease) . Drugs . 1995;50:854–872
  16. Miller-Larsson A , Gustafson B , Persson CG , Brattsand R . Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat . Aliment Pharmacol Ther . 2001;15:2019–2025
  17. Edsbacker S, Bengtsson B, Larsson P, Larsson P, Lundin P, Nilsson A, et al. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules . Aliment Pharmacol Ther . 2003;17:525–536
  18. Lundin PD, Edsbacker S, Bergstrand M, Bergstrand M, Ejderhamn J, Linander H, et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease . Aliment Pharmacol Ther . 2003;17:85–92
  19. Greenberg GR, Feagan BG, Martin F, Martin F, Sutherland LR, Thomson AB, et al. Oral budesonide for active Crohn's disease (Canadian Inflammatory Bowel Disease Study Group) . N Engl J Med . 1994;331:836–841
  20. Thomsen OO, Cortot A, Jewel D, Wright JP, Winter T, Veloso FT, et al. A comparison of budesonide and mesalamine for active Crohn's disease (International Budesonide-Mesalamine Study Group) . N Engl J Med . 1998;339:370–374
  21. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease . N Engl J Med . 1994;331:842–845
  22. Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease (German/Austrian Budesonide Study Group) . Eur J Gastroenterol Hepatol . 1996;8:905–909
  23. Campieri M , Ferguson A , Doe W , Persson T , Nilsson LG . Oral budesonide is as effective as oral prednisolone in active Crohn's disease (The Global Budesonide Study Group) . Gut . 1997;41:209–214
  24. Kane SV , Schoenfeld P , Sandborn WJ , Tremaine W , Hofer T , Feagan BG . The effectiveness of budesonide therapy for Crohn's disease . Aliment Pharmacol Ther . 2002;16:1509–1517
  25. Marshall JK , Irvine EJ . Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis . Gut . 1997;40:775–781
  26. Cohen RD , Woseth DM , Thisted RA , Hanauer SB . A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis . Am J Gastroenterol . 2000;95:1263–1276
  27. Mulder CJ , Fockens P , Meijer JW , van der Heide H , Wiltink EH , Tytgat GN . Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis . Eur J Gastroenterol Hepatol . 1996;8:549–553
  28. Somerville KW , Langman MJ , Kane SP , MacGilchrist AJ , Watkinson G , Salmon P . Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas . Br Med J (Clin Res Ed) . 1985;291:866
  29. Braverman DL , Lachmann EA , Nagler W . Avascular necrosis of bilateral knees secondary to corticosteroid enemas . Arch Phys Med Rehabil . 1998;79:449–452
  30. Danielsson A, Hellers G, Lyrenas E, Lofberg R, Nilsson A, Olsson O, et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis . Scand J Gastroenterol . 1987;22:987–992
  31. The Danish Budesonide Study Group . Budesonide enema in distal ulcerative colitis (A randomized dose-response trial with prednisolone enema as positive control) . Scand J Gastroenterol . 1991;26:1225–1230
  32. Lofberg R, Ostergaard Thomsen O, Langholz E, Langholz E, Schioler R, Danielsson A, et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis . Aliment Pharmacol Ther . 1994;8:623–629
  33. Lemann M, Galian A, Rutgeerts P, Van Heuverzwijn R, Cortot A, Viteau JM, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis . Aliment Pharmacol Ther . 1995;9:557–562
  34. Bianchi Porro G , Prantera C , Campieri M . Comparative trial of methylprednisolone and budesonide enemas in inactive distal ulcerative colitis . Eur J Gastroenterol Hepatol . 1994;6:125–130
  35. Bar-Meir S, Fidder HH, Faszczyk M, Bianchi Porro G, Sturniolo GC, Mickisch O, et al. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis . Dis Colon Rectum . 2003;46:929–936
  36. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, et al. National Cooperative Crohn's Disease Study: results of drug treatment . Gastroenterology . 1979;77:847–869
  37. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment . Gastroenterology . 1984;86:249–266
  38. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease (Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives) . Gastroenterology . 1990;98:811–818
  39. Shaffer JA , Williams SE , Turnberg LA , Houston JB , Rowland M . Absorption of prednisolone in patients with Crohn's disease . Gut . 1983;24:182–186
  40. Faubion WA , Loftus EV , Harmsen WS , Zinsmeister AR , Sandborn WJ . The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study . Gastroenterology . 2001;121:255–260
  41. Munkholm P , Langholz E , Davidsen M , Binder V . Frequency of glucocorticoid resistance and dependency in Crohn's disease . Gut . 1994;35:360–362
  42. Truelove SC , Witts LJ . Cortisone in ulcerative colitis; preliminary report on a therapeutic trial . Br Med J . 1954;4884:375–378
  43. Truelove SC , Witts LJ . Cortisone in ulcerative colitis; final report on a therapeutic trial . Br Med J . 1955;4947:1041–1048
  44. Truelove SC , Watkinson G , Draper G . Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis . Br Med J . 1962;5321:1708–1711
  45. Van Hees PA, Van Lier HJ, Van Elteren PH, Driessen M, Van Hogezand RA, Ten Velde GP, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study . Gut . 1981;22:404–409
  46. Truelove SC , Willoughby CP , Lee EG , Kettlewell MG . Further experience in the treatment of severe attacks of ulcerative colitis . Lancet . 1978;2:1086–1088
  47. Truelove SC , Jewell DP . Intensive intravenous regimen for severe attacks of ulcerative colitis . Lancet . 1974;1:1067–1070
  48. Meyers S , Sachar DB , Goldberg JD , Janowitz HD . Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis (A prospective, randomized, double-blind clinical trial) . Gastroenterology . 1983;85:351–357
  49. Powell-Tuck J , Buckell NA , Lennard-Jones JE . A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis . Scand J Gastroenterol . 1977;12:971–975
  50. Kaplan HP , Portnoy B , Binder HJ , Amatruda T , Spiro H . A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis . Gastroenterology . 1975;69:91–95
  51. Jarnerot G , Rolny P , Sandberg-Gertzen H . Intensive intravenous treatment of ulcerative colitis . Gastroenterology . 1985;89:1005–1013
  52. Shepherd HA , Barr GD , Jewell DP . Use of an intravenous steroid regimen in the treatment of acute Crohn's disease . J Clin Gastroenterol . 1986;8:154–159
  53. Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, et al. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up . Inflamm Bowel Dis . 1998;4:177–181
  54. Truelove SC , Witts LJ . Cortisone and corticotrophin in ulcerative colitis . Br Med J . 1959;34:387–394
  55. Lennard-Jones JE , Mickiewicz JJ , Connell AM , Baron JH , Jones FA . Prednisone as maintenance treatment for ulcerative colitis in remission . Lancet . 1965;191:188–189
  56. Powell-Tuck J , Bown RL , Chambers TJ , Lennard-Jones JE . A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission . Digestion . 1981;22:263–270
  57. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study (Canadian Inflammatory Bowel Disease Study Group) . Gastroenterology . 1996;110:45–51
  58. Lofberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson A, Olaison G, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease (A placebo controlled one year study) . Gut . 1996;39:82–86
  59. Ferguson A , Campieri M , Doe W , Persson T , Nygard G . Oral budesonide as maintenance therapy in Crohn's disease—results of a 12-month study (Global Budesonide Study Group) . Aliment Pharmacol Ther . 1998;12:175–183
  60. Gross V, Andus T, Ecker KW, Raedler A, Loeschke K, Plauth M, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease (The Budesonide Study Group) . Gut . 1998;42:493–496
  61. Hanauer S , Sandborn WJ , Persson A , Persson T . Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial . Aliment Pharmacol Ther . 2005;21:363–371
  62. Sandborn WJ , Lofberg R , Feagan BG , Hanauer SB , Campieri M , Greenberg GR . Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials . Am J Gastroenterol . 2005;100:1780–1787
  63. Ewe K , Bottger T , Buhr HJ , Ecker KW , Otto HF . Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial (German Budesonide Study Group) . Eur J Gastroenterol Hepatol . 1999;11:277–282
  64. Hellers G, Cortot A, Jewell D, Leijonmarck CE, Lofberg R, Malchow H, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease (The IOIBD Budesonide Study Group) . Gastroenterology . 1999;116:294–300
  65. Mantzaris G , Petraki K , Chadio-Iordanides H , et al.  Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease . (abstr) Gastroenterology . 2002;122:A-81
  66. Baron JH , Connell AM , Kanaghinis TG , Lennard-Jones JE , Jones AF . Out-patient treatment of ulcerative colitis (Comparison between three doses of oral prednisone) . Br Med J . 1962;5302:441–443
  67. Powell-Tuck J , Bown RL , Lennard-Jones JE . A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis . Scand J Gastroenterol . 1978;13:833–837
  68. Berghouse LM , Elliott PR , Lennard-Jones JE , English J , Marks V . Plasma prednisolone levels during intravenous therapy in acute colitis . Gut . 1982;23:980–983
  69. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial (The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives) . Gastroenterology . 1992;102:1647–1653
  70. Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance (Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives) . Gastroenterology . 1996;110:688–693
  71. Brignola C, De Simone G, Iannone P, Belloli C, Evangelisti A, Campieri M, et al. Influence of steroid treatment's duration in patients with active Crohn's disease. . gents Actions . 1992;C90–C92 Spec
  72. Cortot A, Colombel JF, Rutgeerts P, Lauritsen K, Malchow H, Hamling J, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease . Gut . 2001;48:186–190
  73. Singleton JW , Law DH , Kelley ML , Mekhjian HS , Sturdevant RA . National Cooperative Crohn's Disease Study: adverse reactions to study drugs . Gastroenterology . 1979;77:870–882
  74. Aberra FN , Lewis JD , Hass D , Rombeau JL , Osborne B , Lichtenstein GR . Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients . Gastroenterology . 2003;125:320–327
  75. Bernstein CN , Leslie WD , Leboff MS . AGA technical review on osteoporosis in gastrointestinal diseases . Gastroenterology . 2003;124:795–841
  76. Haderslev KV , Tjellesen L , Sorensen HA , Staun M . Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease . Gastroenterology . 2000;119:639–646
  77. Clements D , Compston JE , Evans WD , Rhodes J . Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease . Gut . 1993;34:1543–1546
  78. Yang YX , Lichtenstein GR . Corticosteroids in Crohn's disease . Am J Gastroenterol . 2002;97:803–823
  79. Liu YF, Chen WM, Lin YF, Yang RC, Lin MW, Li LH, et al. Type II collagen gene variants and inherited osteonecrosis of the femoral head . N Engl J Med . 2005;352:2294–2301
  80. Schoon EJ, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease . Clin Gastroenterol Hepatol . 2005;3:113–121
  81. Cooper MS , Stewart PM . Corticosteroid insufficiency in acutely ill patients . N Engl J Med . 2003;348:727–734
  82. Lichtenstein GR . Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy . Gastroenterology . 2004;127:1558–1564
  83. Lennard L . The clinical pharmacology of 6-mercaptopurine . Eur J Clin Pharmacol . 1992;43:329–339
  84. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease . Gastroenterology . 2000;118:705–713
  85. Cuffari C , Hunt S , Bayless T . Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease . Gut . 2001;48:642–646
  86. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease . Gut . 2001;49:665–670
  87. Gupta P , Gokhale R , Kirschner BS . 6-mercaptopurine metabolite levels in children with inflammatory bowel disease . J Pediatr Gastroenterol Nutr . 2001;33:450–454
  88. Aberra FN , Lichtenstein GR . Review article: monitoring of immunomodulators in inflammatory bowel disease . Aliment Pharmacol Ther . 2005;21:307–319
  89. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease . Gastroenterology . 2002;122:904–915
  90. Weinshilboum RM , Sladek SL . Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity . Am J Hum Genet . 1980;32:651–662
  91. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy . Gastroenterology . 2000;118:1025–1030
  92. Package insert for azathioprine/6-mercaptopurine. Imuran®, Prometheus Laboratories, Inc., San Diego, California, 2005.
  93. Connell WR , Kamm MA , Dickson M , Balkwill AM , Ritchie JK , Lennard-Jones JE . Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease . Lancet . 1994;343:1249–1252
  94. Present DH , Meltzer SJ , Krumholz MP , Wolke A , Korelitz BI . 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity . Ann Intern Med . 1989;111:641–649
  95. Sandborn WJ . A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate . Am J Gastroenterol . 1996;91:423–433
  96. Haber CJ , Meltzer SJ , Present DH , Korelitz BI . Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease . Gastroenterology . 1986;91:982–986
  97. Korelitz BI , Zlatanic J , Goel F , Fuller S . Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease . J Clin Gastroenterol . 1999;28:341–344
  98. Cheng B , Lichtenstein G . Are individuals with Crohn's disease who are intolerant to 6-mercaptopurine able to tolerate azathioprine? . (abstr) Gastroenterology . 2000;118:A1336
  99. Boulton-Jones JR , Pritchard K , Mahmoud AA . The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy . Aliment Pharmacol Ther . 2000;14:1561–1565
  100. George J , Present DH , Pou R , Bodian C , Rubin PH . The long-term outcome of ulcerative colitis treated with 6-mercaptopurine . Am J Gastroenterol . 1996;91:1711–1714
  101. Korelitz BI , Fuller SR , Warman JI , Goldberg MD . Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease . Am J Gastroenterol . 1999;94:424–426
  102. Pfau P , Kochman ML , Furth EE , Lichtenstein GR . Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient . Am J Gastroenterol . 2001;96:895–899
  103. Pearson DC , May GR , Fick GH , Sutherland LR . Azathioprine and 6-mercaptopurine in Crohn disease (A meta-analysis) . Ann Intern Med . 1995;123:132–142
  104. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide . Gut . 2001;49:656–664
  105. Szumlanski CL , Weinshilboum RM . Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine . Br J Clin Pharmacol . 1995;39:456–459
  106. Lewis LD , Benin A , Szumlanski CL Otterness DM , Lennard L , Weinshilboum RM , Nierenberg DW . Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction . Clin Pharmacol Ther . 1997;62:464–475
  107. Gardiner S , Begg E , Barclay M , Kirkpatrick C . Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine . Adverse Drug React Toxicol Rev . 2000;19:293–312
  108. Peppercorn MA . 6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come . Am J Gastroenterol . 1996;91:1689–1690
  109. Lewis JD , Schwartz JS , Lichtenstein GR . Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma . Gastroenterology . 2000;118:1018–1024
  110. Kandiel A , Fraser AG , Korelitz BI , Brensinger C , Lewis JD . Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine . Gut . 2005;54:1121–1125
  111. Winter J , Walker A , Shapiro D , Gaffney D , Spooner RJ , Mills PR . Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease . Aliment Pharmacol Ther . 2004;20:593–599
  112. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine . Ann Intern Med . 1998;129:716–718
  113. Seddik M , Texier F , Ferrari N , et al.  Thiopurine S-methyltransferase genotyping does not predict azathioprine-induced myelosuppression in Crohn's disease . (abstr) Gastroenterology . 2003;124:A311
  114. Curvers W , Derijks L , Stokkers P , et al.  No predictive value of TPMT genotyping for leukopenia or hepatotoxicity during azathioprine therapy for inflammatory bowel disease . (abstr) Gastroenterology . 2003;124:A377
  115. Sebbag L, Boucher P, Davelu P, Boissonnat P, Champsaur G, Ninet J, et al. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients . Transplantation . 2000;69:1524–1527
  116. Kaskas BA, Louis E, Hindorf U, Schaeffeler E, Deflandre J, Graepler F, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine . Gut . 2003;52:140–142
  117. Su C , Lichtenstein GR . Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine . Gastroenterol Clin North Am . 2004;33:209–234 viii
  118. Brooke BN , Hoffmann DC , Swarbrick ET . Azathioprine for Crohn's disease . Lancet . 1969;2:612–614
  119. Rhodes J , Bainton D , Beck P , Campbell H . Controlled trial of azathioprine in Crohn's disease . Lancet . 1971;2:1273–1276
  120. Willoughby JM , Beckett J , Kumar PJ , Dawson AM . Controlled trial of azathioprine in Crohn's disease . Lancet . 1971;2:944–947
  121. Klein M , Binder HJ , Mitchell M , Aaronson R , Spiro H . Treatment of Crohn's disease with azathioprine: a controlled evaluation . Gastroenterology . 1974;66:916–922
  122. Present DH , Korelitz BI , Wisch N , Glass JL , Sachar DB , Pasternack BS . Treatment of Crohn's disease with 6-mercaptopurine (A long-term, randomized, double-blind study) . N Engl J Med . 1980;302:981–987
  123. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease . Gastroenterology . 1993;105:367–372
  124. Candy S , Wright J , Gerber M , Adams G , Gerig M , Goodman R . A controlled double blind study of azathioprine in the management of Crohn's disease . Gut . 1995;37:674–678
  125. Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial . Am J Gastroenterol . 1997;92:2203–2209
  126. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis . BMJ . 1992;305:20–22
  127. Jewell DP , Truelove SC . Azathioprine in ulcerative colitis: final report on controlled therapeutic trial . Br Med J . 1974;4:627–630
  128. Rosenberg JL , Wall AJ , Levin B , Binder HJ , Kirsner JB . A controlled trial of azathioprine in the management of chronic ulcerative colitis . Gastroenterology . 1975;69:96–99
  129. Kirk AP , Lennard-Jones JE . Controlled trial of azathioprine in chronic ulcerative colitis . Br Med J (Clin Res Ed) . 1982;284:1291–1292
  130. Caprilli R , Carratu R , Babbini M . Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis (Preliminary report) . Am J Dig Dis . 1975;20:115–120
  131. Ardizzone S , Samolvico F , Bollani S , Imbesi V , Colombo E , Bianchi Porro G . Azathioprine is more effective than oral 5-ASA in the treatment of steroid-dependent ulcerative colitis . (abstr) Gastroenterology . 2001;120:A127
  132. Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis . Am J Gastroenterol . 2004;99:1122–1128
  133. Sood A , Midha V , Sood N , Kaushal V . Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial . Indian J Gastroenterol . 2000;19:14–16
  134. Cohen RD , Stein R , Hanauer SB . Intravenous cyclosporin in ulcerative colitis: a five-year experience . Am J Gastroenterol . 1999;94:1587–1592
  135. Fernandez-Banares F, Bertran X, Esteve-Comas M, Cabre E, Menacho M, Humbert P, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis . Am J Gastroenterol . 1996;91:2498–2499
  136. Domenech E, Garcia-Planella E, Bernal I, Rosinach M, Cabre E, Fluvia L, et al. Azathioprine without oral cyclosporin in the long-term maintenance of remission induced by intravenous cyclosporin in severe, steroid-refractory ulcerative colitis . Aliment Pharmacol Ther . 2002;16:2061–2065
  137. Markowitz J , Grancher K , Kohn N , Lesser M , Daum F . A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease . Gastroenterology . 2000;119:895–902
  138. Rosenberg JL , Levin B , Wall AJ , Kirsner JB . A controlled trial of azathioprine in Crohn's disease . Am J Dig Dis . 1975;20:721–726
  139. O'Donoghue DP , Dawson AM , Powell-Tuck J , Brown RL , Lennard-Jones JE . Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease . Lancet . 1978;2:955–957
  140. Achkar JP , Hanauer SB . Medical therapy to reduce postoperative Crohn's disease recurrence . Am J Gastroenterol . 2000;95:1139–1146
  141. Olaison G , Smedh K , Sjodahl R . Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms . Gut . 1992;33:331–335
  142. Rutgeerts P , Geboes K , Vantrappen G , Beyls J , Kerremans R , Hiele M . Predictability of the postoperative course of Crohn's disease . Gastroenterology . 1990;99:956–963
  143. Lautenbach E , Berlin JA , Lichtenstein GR . Risk factors for early postoperative recurrence of Crohn's disease . Gastroenterology . 1998;115:259–267
  144. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection . Gastroenterology . 1995;108:1617–1621
  145. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial . Gastroenterology . 2005;128:856–861
  146. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial . Gastroenterology . 2004;127:723–729
  147. Sandborn WJ , Feagan BG . The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain . Gastroenterology . 2004;127:990–993
  148. Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease . Gastroenterology . 2004;127:730–740
  149. Hanauer S , Cohen R , Thisted R , Rutgeerts P , Present D , Korelitz B . Reply to: 6-mercaptopurine and mesalamine for prevention of relapse after conservative therapy for Crohn's disease . (letter) Gastroenterology . 2005;128:249–251
  150. Feagan BG, Rochon J, Fedorak RN, Irvine JE, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn's disease (The North American Crohn's Study Group Investigators) . N Engl J Med . 1995;332:292–297
  151. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial . Gastroenterology . 1996;110:1416–1421
  152. Arora S, Katkov W, Cooley J, Kemp JA, Johnston DE, Schapiro RH, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial . Hepatogastroenterology . 1999;46:1724–1729
  153. Feagan BG, Fedorak RN, Irvine EJ, Sutherland L, Steinhart AH, Greenberg GR, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease (North American Crohn's Study Group Investigators) . N Engl J Med . 2000;342:1627–1632
  154. Chong RY , Hanauer SB , Cohen RD . Efficacy of parenteral methotrexate in refractory Crohn's disease . Aliment Pharmacol Ther . 2001;15:35–44
  155. Fraser G , Ben-Bassat O , Segal N , Fishman-Mor M , Niv Y . Parenteral methotrexate is not effective treatment for refractory ulcerative colitis . Gastroenterology . 2003;124(Suppl 1):A525
  156. Cummings JR , Herrlinger KR , Travis SP , Gorard DA , McIntyre AS , Jewell DP . Oral methotrexate in ulcerative colitis . Aliment Pharmacol Ther . 2005;21:385–389
  157. Mahadevan U , Marion JF , Present DH . Fistula response to methotrexate in Crohn's disease: a case series . Aliment Pharmacol Ther . 2003;18:1003–1008
  158. Vandeputte L , D'Haens G , Baert F , Rutgeerts P . Methotrexate in refractory Crohn's disease . Inflamm Bowel Dis . 1999;5:11–15
  159. Campbell MS , Reddy KR . Review article: the evolving role of liver biopsy . Aliment Pharmacol Ther . 2004;20:249–259
  160. Kozarek R , Brefeldt J , Rosoff L , Patterson D , Fenster L . Does methotrexate (MTX) cause liver toxicity when used for refractory inflammatory bowel disease (IBD)? . (abstr) Gastroenterology . 1991;100:A221
  161. Te HS , Schiano TD , Kuan SF , Hanauer SB , Conjeevaram HS , Baker AL . Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease . Am J Gastroenterol . 2000;95:3150–3156
  162. Kremer JM, Alarcon GS, Lightfoot RW, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis (Suggested guidelines for monitoring liver toxicity. American College of Rheumatology) . Arthritis Rheum . 1994;37:316–328
  163. Kremer JM , Galivan J , Streckfuss A , Kamen B . Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients (Association with hepatic folate deficiency and formation of polyglutamates) . Arthritis Rheum . 1986;29:832–835
  164. Schilsky RL , Lewis BJ , Sherins RJ , Young RC . Gonadal dysfunction in patients receiving chemotherapy for cancer . Ann Intern Med . 1980;93:109–114
  165. Rustin GJ , Booth M , Dent J , Salt S , Rustin F , Bagshawe KD . Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours . Br Med J (Clin Res Ed) . 1984;288:103–106
  166. Weissbach L , Lange CE , Rodermund OE , Zwicker H , Gropp A , Pothmann W . [Fertility disturbances following treatment of patients with testicular tumors (author's transl)] . Urologe A . 1974;13:80–85
  167. Hinkes E , Plotkin D . Reversible drug-induced sterility in a patient with acute leukemia . JAMA . 1973;223:1490–1491
  168. Sussman A , Leonard JM . Psoriasis, methotrexate, and oligospermia . Arch Dermatol . 1980;116:215–217
  169. Milunsky A , Graef JW , Gaynor MF . Methotrexate-induced congenital malformations . J Pediatr . 1968;72:790–795
  170. Powell HR , Ekert H . Methotrexate-induced congenital malformations . Med J Aust . 1971;2:1076–1077
  171. Pizzuto J , Aviles A , Noriega L , Niz J , Morales M , Romero F . Treatment of acute leukemia during pregnancy: presentation of nine cases . Cancer Treat Rep . 1980;64:679–683
  172. Okun DB , Groncy PK , Sieger L , Tanaka KR . Acute leukemia in pregnancy: transient neonatal myelosuppression after combination chemotherapy in the mother . Med Pediatr Oncol . 1979;7:315–319
  173. Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation. 5th ed. Baltimore, MD: Williams and Wilkins, 1998.
  174. American Academy of Pediatrics Committee on Drugs . The transfer of drugs and other chemicals into human milk . Pediatrics . 1994;93:137–150
  175. Kitchin JE , Pomeranz MK , Pak G , Washenik K , Shupack JL . Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses . J Am Acad Dermatol . 1997;37:445–449
  176. Fickert P , Hinterleitner TA , Wenzl HH , Aichbichler BW , Petritsch W . Mycophenolate mofetil in patients with Crohn's disease . Am J Gastroenterol . 1998;93:2529–2532
  177. Neurath MF , Wanitschke R , Peters M , Krummenauer F , Meyer zum Buschenfelde KH , Schlaak JF . Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease . Gut . 1999;44:625–628
  178. Orth T, Peters M, Schlaak JF, Krummenauer F, Wanitschke R, Mayet WJ, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study . Am J Gastroenterol . 2000;95:1201–1207
  179. Hassard PV , Vasiliauskas EA , Kam LY , Targan SR , Abreu MT . Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease . Inflamm Bowel Dis . 2000;6:16–20
  180. Fellermann K, Steffen M, Stein J, Raedler A, Hamling J, Ludwig D, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease . Aliment Pharmacol Ther . 2000;14:171–176
  181. Miehsler W , Reinisch W , Moser G , Gangl A , Vogelsang H . Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? . Am J Gastroenterol . 2001;96:782–787
  182. Hafraoui S, Dewit O, Marteau P, Cosnes J, Colombel JF, Modigliani R, et al. [Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate . ] Gastroenterol Clin Biol . 2002;26:17–22
  183. Skelly MM , Logan RF , Jenkins D , Mahida YR , Hawkey CJ . Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease . Inflamm Bowel Dis . 2002;8:93–97
  184. Papadimitriou JC, Cangro CB, Lustberg A, Khaled A, Nogueira J, Wiland A, et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern . Int J Surg Pathol . 2003;11:295–302
  185. Dalle IJ , Maes BD , Geboes KP , Lemahieu W , Geboes K . Crohn's-like changes in the colon due to mycophenolate? . Colorectal Dis . 2005;7:27–34
  186. Borel JF , Feurer C , Gubler HU , Stahelin H . Biological effects of cyclosporin A: a new antilymphocytic agent . Agents Actions . 1976;6:468–475
  187. Liu J , Farmer JD , Lane WS , Friedman J , Weissman I , Schreiber SL . Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes . Cell . 1991;66:807–815
  188. Schreiber SL , Crabtree GR . The mechanism of action of cyclosporin A and FK506 . Immunol Today . 1992;13:136–142
  189. Gupta S , Keshavarzian A , Hodgson HJ . Cyclosporin in ulcerative colitis . Lancet . 1984;2:1277–1278
  190. Hyams JS , Treem WR . Cyclosporine treatment of fulminant colitis . J Pediatr Gastroenterol Nutr . 1989;9:383–387
  191. Lichtiger S , Present DH . Preliminary report: cyclosporin in treatment of severe active ulcerative colitis . Lancet . 1990;336:16–19
  192. Porro GB , Petrillo M , Ardizzone S . Cyclosporin treatment for severe active ulcerative colitis . Lancet . 1990;336:439
  193. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy . N Engl J Med . 1994;330:1841–1845
  194. Santos J , Baudet S , Casellas F , Guarner L , Vilaseca J , Malagelada JR . Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis . J Clin Gastroenterol . 1995;20:285–289
  195. Treem WR , Cohen J , Davis PM , Justinich CJ , Hyams JS . Cyclosporine for the treatment of fulminant ulcerative colitis in children (Immediate response, long-term results, and impact on surgery) . Dis Colon Rectum . 1995;38:474–479
  196. Kornbluth A , Lichtiger S , Present D , Hanauer S . Long-term results of oral cyclosporine in patients with severe ulcerative colitis: a double-blind, randomized, multi-center trial . (abstr) Gastroenterology . 1994;106:A714
  197. Carbonnel F, Boruchowicz A, Duclos B, Soule JC, Lerebours E, Lemann M, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses . Dig Dis Sci . 1996;41:2471–2476
  198. Van Gossum A, Schmit A, Adler M, Chioccioli C, Fiasse R, Louwagie P, et al. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis (Belgian IBD Group) . Acta Gastroenterol Belg . 1997;60:197–200
  199. Kornbluth A , Present DH , Lichtiger S , Hanauer S . Cyclosporin for severe ulcerative colitis: a user's guide . Am J Gastroenterol . 1997;92:1424–1428
  200. Kornbluth A , Sachar DB . Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee . Am J Gastroenterol . 2004;99:1371–1385
  201. Smith MB , Hanauer SB . Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis . N Engl J Med . 1992;327:497–498
  202. Sandborn W . A critical review of cyclosporine therapy in inflammatory bowel disease . Inflamm Bowel Dis . 1995;1:48–63
  203. Schutz E, Svinarov D, Shipkova M, Niedmann PD, Armstrong VW, Wieland E, et al. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC . Clin Chem . 1998;44:2158–2164
  204. Vermeire S , Rutgeerts P . Cyclosporine monotherapy is effective in the treatment of severe ulcerative colitis . Inflamm Bowel Dis . 1996;2:253–254
  205. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis . Gastroenterology . 2001;120:1323–1329
  206. Cohen RD . Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone? . Gastroenterology . 2001;120:1541–1543
  207. Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis . Gastroenterology . 2003;125:1025–1031
  208. Allam BF , Tillman JE , Thomson TJ , Crossling FT , Gilbert LM . Effective intravenous cyclosporin therapy in a patient with severe Crohn's disease on parenteral nutrition . Gut . 1987;28:1166–1169
  209. Lobo AJ , Juby LD , Rothwell J , Poole TW , Axon AT . Long-term treatment of Crohn's disease with cyclosporine: the effect of a very low dose on maintenance of remission . J Clin Gastroenterol . 1991;13:42–45
  210. Lichtiger S . Cyclosporine therapy in inflammatory bowel disease: open-label experience . Mt Sinai J Med . 1990;57:315–319
  211. Mahdi G , Israel DM , Hassall E . Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children . Am J Gastroenterol . 1996;91:1355–1359
  212. Egan LJ , Sandborn WJ , Tremaine WJ . Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine . Am J Gastroenterol . 1998;93:442–448
  213. Present DH , Lichtiger S . Efficacy of cyclosporine in treatment of fistula of Crohn's disease . Dig Dis Sci . 1994;39:374–380
  214. Hinterleitner TA , Petritsch W , Aichbichler B , Fickert P , Ranner G , Krejs GJ . Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease . Z Gastroenterol . 1997;35:603–608
  215. Judge TA , Lichtenstein GR . Treatment of fistulizing Crohn's disease . Gastroenterol Clin North Am . 2004;33:421–454 xi–xii
  216. Drewe J, Meier R, Vonderscher J, Kiss D, Posanski U, Kissel T, et al. Enhancement of the oral absorption of cyclosporin in man . Br J Clin Pharmacol . 1992;34:60–64
  217. Mueller EA , Kovarik JM , van Bree JB , Tetzloff W , Grevel J , Kutz K . Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation . Pharm Res . 1994;11:301–304
  218. Kovarik JM , Mueller EA , Johnston A , Hitzenberger G , Kutz K . Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation . Pharmacotherapy . 1993;13:613–617
  219. Frei UA , Neumayer HH , Buchholz B , Niese D , Mueller EA . Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients (International Sandimmun Neoral Study Group) . Transplantation . 1998;65:1455–1460
  220. Actis GC , Aimo G , Priolo G , Moscato D , Rizzetto M , Pagni R . Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial . Inflamm Bowel Dis . 1998;4:276–279
  221. Actis GC , Volpes R , Rizzetto M . Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis . Eur J Gastroenterol Hepatol . 1999;11:905–908
  222. Navazo L, Salata H, Morales S, Dorta MC, Perez F, de las Casas D, et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis . Scand J Gastroenterol . 2001;36:610–614
  223. Brynskov J, Freund L, Rasmussen SN, Lauritsen K, de Muckadell OS, Williams N, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease . N Engl J Med . 1989;321:845–850
  224. Brynskov J, Freund L, Norby Rasmussen S, Rasmussen S, Lauritsen K, Schaffalitzky de Muckadell O, et al  Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease . Scand J Gastroenterol . 1991;26:689–695
  225. Jewell DP , Lennard-Jones JE . Oral cyclosporine for chronic active Crohn's disease: a multicentre controlled trial . Eur J Gastroenterol Hepatol . 1994;6:499–505
  226. Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, et al. Low-dose cyclosporine for the treatment of Crohn's disease (The Canadian Crohn's Relapse Prevention Trial Investigators) . N Engl J Med . 1994;330:1846–1851
  227. Stange EF , Modigliani R , Pena AS , Wood AJ , Feutren G , Smith PR . European trial of cyclosporine in chronic active Crohn's disease: a 12-month study (The European Study Group) . Gastroenterology . 1995;109:774–782
  228. Feagan BG , McDonald JW . Cyclosporin in Crohn's disease . Lancet . 1997;349:1328
  229. McDonald JW , Feagan BG , Jewell D , Brynskov J , Stange EF , Macdonald JK . Cyclosporine for induction of remission in Crohn's disease . Cochrane Database Syst Rev . 2005;2:CD000297
  230. Brynskov J , Freund L , Thomsen OO , Andersen CB , Rasmussen SN , Binder V . Treatment of refractory ulcerative colitis with cyclosporin enemas . Lancet . 1989;1:721–722
  231. Ranzi T , Campanini MC , Velio P , Quarto di Palo F , Bianchi P . Treatment of chronic proctosigmoiditis with cyclosporin enemas . Lancet . 1989;2:97
  232. Sandborn WJ , Tremaine WJ , Schroeder KW , Steiner BL , Batts KP , Lawson GM . Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis . Am J Gastroenterol . 1993;88:640–645
  233. Winter TA , Dalton HR , Merrett MN , Campbell A , Jewell DP . Cyclosporin A retention enemas in refractory distal ulcerative colitis and “pouchitis.” . Scand J Gastroenterol . 1993;28:701–704
  234. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis . Gastroenterology . 1994;106:1429–1435
  235. Flanagan WM , Corthesy B , Bram RJ , Crabtree GR . Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A . Nature . 1991;352:803–807
  236. Bousvaros A, Kirschner BS, Werlin SL, Parker-Hartigan L, Daum F, Freeman KB, et al. Oral tacrolimus treatment of severe colitis in children . J Pediatr . 2000;137:794–799
  237. Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506) . Inflamm Bowel Dis . 2002;8:317–324
  238. Hogenauer C , Wenzl HH , Hinterleitner TA , Petritsch W . Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis . Aliment Pharmacol Ther . 2003;18:415–423
  239. Lowry PW , Weaver AL , Tremaine WJ , Sandborn WJ . Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae . Inflamm Bowel Dis . 1999;5:239–245
  240. Ierardi E, Principi M, Rendina M, Francavilla R, Ingrosso M, Pisani A, et al. Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum . J Clin Gastroenterol . 2000;30:200–202
  241. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial . Gastroenterology . 2003;125:380–388
  242. Van Deventer SJ . Tumour necrosis factor and Crohn's disease . Gut . 1997;40:443–448
  243. Physician's Desk Reference. 59th ed. Montvale, NJ: Medical Economics Co, 2005.
  244. Physician's Desk Reference. 58th ed. Montvale, NJ: Medical Economics Co, 2004.
  245. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) . Gastroenterology . 1995;109:129–135
  246. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease (Crohn's Disease cA2 Study Group) . N Engl J Med . 1997;337:1029–1035
  247. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease . Gastroenterology . 1999;117:761–769
  248. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial . Lancet . 2002;359:1541–1549
  249. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease . Gastroenterology . 2004;126:402–413
  250. Sartor RB . Episodic retreatment versus scheduled maintenance therapy of Crohn's disease with infliximab: not so far apart . Gastroenterology . 2004;126:598–601
  251. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease . N Engl J Med . 2003;348:601–608
  252. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease . Clin Gastroenterol Hepatol . 2004;2:542–553
  253. Farrell RJ , Alsahli M , Jeen YT , Falchuk KR , Peppercorn MA , Michetti P . Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial . Gastroenterology . 2003;124:917–924
  254. Sandborn WJ . Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize . Gastroenterology . 2003;124:1140–1145
  255. Lemann M, Colombel J, Duclos B, Veyrac M, Dupas J, Delchier J, Laharie D, Moreau J, Dadiot G, Sobhani I, Metman E, Boureille A. Infliximab in steroid dependent Crohn's Disease patients treated with azathioprine or 6-MP: a randomized double-blind placebo-controlled trial (abstr). Gut 203;52(Suppl):A44.
  256. Hochberg MC , Tracy JK , Hawkins-Holt M , Flores RH . Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis . Ann Rheum Dis . 2003;62(Suppl 2):13–16
  257. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease . N Engl J Med . 1999;340:1398–1405
  258. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease . N Engl J Med . 2004;350:876–885
  259. van Bodegraven AA , Sloots CE , Felt-Bersma RJ , Meuwissen SG . Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response . Dis Colon Rectum . 2002;45:39–45 discussion 46
  260. Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease . Am J Gastroenterol . 2003;98:332–339
  261. Poritz LS , Rowe WA , Koltun WA . Remicade does not abolish the need for surgery in fistulizing Crohn's disease . Dis Colon Rectum . 2002;45:771–775
  262. Sands BE , Blank MA , Patel K , van Deventer SJ . Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study . Clin Gastroenterol Hepatol . 2004;2:912–920
  263. Levy C , Tremaine WJ . Management of internal fistulas in Crohn's disease . Inflamm Bowel Dis . 2002;8:106–111
  264. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study . Inflamm Bowel Dis . 2001;7:83–88
  265. Rutgeerts P, Feagan B, Olson A, Johanns J, Travers S, Present D, et al. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act I trial . (abstr) Gastroenterology . 2005;128:A689
  266. Sandborn W, Rachmilewitz D, Hanauer S, Lichtenstein GR, de Villiers WJ, Olson A, et al. Infliximab induction and maintenance therapy for ulcerative colitis: the Act 2 trial . (abstr) Gastroenterology . 2005;128(Suppl 2):A688
  267. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study . Gastroenterology . 2005;128:1805–1811
  268. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial . Gut . 2003;52:998–1002
  269. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis . N Engl J Med . 2005;353:2462–2476
  270. Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease . Am J Gastroenterol . 2002;97:2688–2690
  271. Rutgeerts P , Van Assche G , Vermeire S . Optimizing anti-TNF treatment in inflammatory bowel disease . Gastroenterology . 2004;126:1593–1610
  272. Bowie VL , Snella KA , Gopalachar AS , Bharadwaj P . Listeria meningitis associated with infliximab . Ann Pharmacother . 2004;38:58–61
  273. Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients . Gastroenterology . 2004;126:19–31
  274. Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, Janczewska I, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County . Gut . 2004;53:849–853
  275. Lichtenstein G, Cohen R, Feagan B, Sandborn WJ, Salzberg BA, Chen DM, et al. Safety of infliximab in Crohn's disease: data from the 5000-patients TREAT Registry . (abstr) Gastroenterology . 2004;126:A54
  276. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management . Lancet Infect Dis . 2003;3:148–155
  277. Mow WS , Abreu-Martin MT , Papadakis KA , Pitchon HE , Targan SR , Vasiliauskas EA . High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy . Clin Gastroenterol Hepatol . 2004;2:309–313
  278. American Thoracic Society, CDC, and Infectious Diseases Society of America . Treatment of tuberculosis . MMWR Morb Mortal Wkly Rep June 20 . 2003;52(RR-11):1–80
  279. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience . Am J Gastroenterol . 2003;98:1315–1324
  280. Sandborn WJ , Hanauer SB . Infliximab in the treatment of Crohn's disease: a user's guide for clinicians . Am J Gastroenterol . 2002;97:2962–2972
  281. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study . Gastroenterology . 2003;125:32–39
  282. Klapman JB , Ene-Stroescu D , Becker MA , Hanauer SB . A lupus-like syndrome associated with infliximab therapy . Inflamm Bowel Dis . 2003;9:176–178
  283. Bernstein CN , Blanchard JF , Kliewer E , Wajda A . Cancer risk in patients with inflammatory bowel disease: a population-based study . Cancer . 2001;91:854–862
  284. Greenstein AJ, Gennuso R, Sachar DB, Heimann T, Smith H, Janowitz HD, et al. Extraintestinal cancers in inflammatory bowel disease . Cancer . 1985;56:2914–2921
  285. Lewis JD , Bilker WB , Brensinger C , Deren JJ , Vaughn DJ , Strom BL . Inflammatory bowel disease is not associated with an increased risk of lymphoma . Gastroenterology . 2001;121:1080–1087
  286. Gyde SN , Prior P , Macartney JC , Thompson H , Waterhouse JA , Allan RN . Malignancy in Crohn's disease . Gut . 1980;21:1024–1029
  287. Ekbom A , Helmick C , Zack M , Adami HO . Extracolonic malignancies in inflammatory bowel disease . Cancer . 1991;67:2015–2019
  288. Persson PG, Karlen P, Bernell O, Leijonmarck CE, Brostrom O, Ahlbom A, et al. Crohn's disease and cancer: a population-based cohort study . Gastroenterology . 1994;107:1675–1679
  289. FDA Board Document. Update on the TNF-alpha blocking agent; 2003. Available at: FDA Board Document. SAFETY OF TNF BLOCKING AGENTS. Accessed Feb 13, 2006. www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_01_B-TNF.Briefing.htm.
  290. Lichtenstein GR, Cohen R, Feagan B, Sandborn WJ, Salzberg BA, Chen D, et al. Safety of infliximab and other Crohn's disease therapies-updated TREAT Registry data with over 10,000 patient-years of follow-up . (abstr). Gastroenterology . 2005;128:A-580
  291. Jess T , Winther KV , Munkholm P , Langholz E , Binder V . Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark . Gastroenterology . 2002;122:1808–1814
  292. Loftus EV , Silverstein MD , Sandborn WJ , Tremaine WJ , Harmsen WS , Zinsmeister AR . Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival . Gastroenterology . 1998;114:1161–1168
  293. Farmer RG , Whelan G , Fazio VW . Long-term follow-up of patients with Crohn's disease (Relationship between the clinical pattern and prognosis) . Gastroenterology . 1985;88:1818–1825
  294. Ekbom A , Helmick CG , Zack M , Holmberg L , Adami HO . Survival and causes of death in patients with inflammatory bowel disease: a population-based study . Gastroenterology . 1992;103:954–960
  295. Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas . Gastroenterology . 2001;121:1064–1072
  296. Talbot C , Sagar PM , Johnston MJ , Finan PJ , Burke D . Infliximab in the surgical management of complex fistulating anal Crohn's disease . Colorectal Dis . 2005;7:164–168
  297. Regueiro M , Valentine J , Plevy S , Fleisher MR , Lichtenstein GR . Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease . Am J Gastroenterol . 2003;98:1821–1826
  298. Kugathasan S , Miranda A , Nocton J , Drolet BA , Raasch C , Binion DG . Dermatologic manifestations of Crohn disease in children: response to infliximab . J Pediatr Gastroenterol Nutr . 2003;37:150–154
  299. Rispo A , Lembo G , Insabato L , Cozzolino A , Pesce G , Castiglione F . Successful treatment of therapy-resistant metastatic Crohn's disease with infliximab . Br J Dermatol . 2004;150:1045–1046
  300. Benitez-Del-Castillo JM, Martinez-De-La-Casa JM, Pato-Cour E, Mendez-Fernandez R, Lopez-Abad C, Matilla M, et al. Long-term treatment of refractory posterior uveitis with anti-TNF alpha (infliximab) . Eye . 2005;19:841–845
  301. Murphy CC , Ayliffe WH , Booth A , Makanjuola D , Andrews PA , Jayne D . Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis . Ophthalmology . 2004;111:352–356
  302. Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study . Ann Rheum Dis . 2003;62:1218–1220
  303. Lupascu A, Armuzzi A, De Pascalis B, Carloni E, Lauritano EC, Gasbarrini A, et al. Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms . Dig Liver Dis . 2004;36:423–425
  304. Kaufman I , Caspi D , Yeshurun D , Dotan I , Yaron M , Elkayam O . The effect of infliximab on extraintestinal manifestations of Crohn's disease . Rheumatol Int . 2005;25:406–410
  305. Freeman HJ , Davis JE , Prest ME , Lawson EJ . Granulomatous bronchiolitis with necrobiotic pulmonary nodules in Crohn's disease . Can J Gastroenterol . 2004;18:687–690
  306. Chung ES , Packer M , Lo KH , Fasanmade AA , Willerson JT . Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial . Circulation . 2003;107:3133–3140
  307. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides . Arthritis Rheum . 2001;44:2862–2869
  308. Nanavati SA , Ergun GA , Schwartz JT . Avoiding infliximab in the treatment of Crohn's disease in patients with multiple sclerosis . Am J Gastroenterol . 2003;98:2333–2334
  309. Thomas CW , Weinshenker BG , Sandborn WJ . Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease . Inflamm Bowel Dis . 2004;10:28–31
  310. Strong BY , Erny BC , Herzenberg H , Razzeca KJ . Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease . Ann Intern Med . 2004;140:W34
  311. Mejico LJ . Infliximab-associated retrobulbar optic neuritis . Arch Ophthalmol . 2004;122:793–794
  312. Sandborn WJ , Loftus EV . Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease . Gut . 2004;53:780–782
  313. Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States . Am J Gastroenterol . 2002;97:1748–1754
  314. Entocort EC [package insert]. Wayne, PA: AstraZeneca Pharmaceuticals, 2005.
  315. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine . Lancet . 1996;347:215–219

 Dr. Lichtenstein is a consultant for Abbott Corporation, Astra-Zeneca, Inc., Axcan Corporation, Berlex, Centocor, Inc., Elan, Genetics Institute, Human Genome Sciences, Inkine, Inc., Intesco Corporation, ISIS Corporation, Millenium Pharmaceuticals, Otsuka Corporation, Proctor and Gamble, Prometheus Laboratories, Inc., Protein Design Labs, Protomed Scientific, Salix Pharmaceuticals, Schering-Plough Corporation, Serono, Shire Pharmaceuticals, Smith Kline Beecham Corporation, Solvay Pharmaceuticals, Synta Pharmaceuticals, UCB, and Wyeth.

 Dr. Tremaine is a consultant for Procter and Gamble, NPS Pharma, and Solvay Pharma.

 Dr. Abreu is a consultant for Procter and Gamble, Abbott, UCB, Prometheus, and Salix.

 Dr. Cohen is a consultant for Salix, Centocor, Abbott, Elan, Isis, Kenwood, McNeil, Pfizer, Protein Design Labs, Astra-Zeneca, Axcan-Scandipharm, Procter and Gamble, Salix, Solvay, and Shire.

 This literature review and the recommendations therein were prepared for the American Gastroenterological Association (AGA) Clinical Practice and Economics Committee. The paper was approved by the Committee on November 22, 2005, and by the AGA Governing Board on January 12, 2006.

 The American Gastroenterological Association received financial support from AstraZeneca LP to retain a contractor to assist in performing the background literature search for this work.

PII: S0016-5085(06)00074-6

doi: 10.1053/j.gastro.2006.01.048

Gastroenterology
Volume 130, Issue 3 , Pages 940-987 , March 2006

Article Tools

* Image Usage & Resolution